|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:boosterInterval
|
every 5 years for high-risk groups
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:brand
|
gptkb:Trumenba
gptkb:Bexsero
gptkb:Menveo
gptkb:Menactra
|
|
gptkbp:broadcastOn
|
multiple doses
|
|
gptkbp:contains
|
antigens from Neisseria meningitidis
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
many other countries
|
|
gptkbp:duration
|
varies by vaccine type
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
meningococcal vaccine
|
|
gptkbp:introducedIn
|
1970s
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
|
|
gptkbp:prevention
|
meningococcal disease
Neisseria meningitidis infection
|
|
gptkbp:protectedBy
|
serogroup A
serogroup B
serogroup C
serogroup W
serogroup Y
|
|
gptkbp:recommendation
|
adolescents
college students
travelers to endemic areas
military recruits
|
|
gptkbp:routeOfAdministration
|
intramuscular
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
pain at injection site
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:type
|
vaccine
recombinant vaccine
polysaccharide vaccine
|
|
gptkbp:usedFor
|
prevention of meningitis
prevention of sepsis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Soliris
gptkb:Neisseria_meningitidis_serogroup_Y
|
|
gptkbp:bfsLayer
|
7
|